珠海赛隆药业股份有限公司 2019 年年度报告全文 珠海赛隆药业股份有限公司 2019 年年度报告 2020 年 04 月 1 珠海赛隆药业股份有限公司 2019 年年度报告全文 第一节重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 公司负责人蔡南桂、主管会计工作负责人高京及会计机构负责人(会计主管 人员)王映娟声明：保证年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 公司年度报告所涉及未来计划等前瞻性陈述不构成公司对投资者的实质承 诺，投资者及相关人士均应当对此保持足够的风险认识，并且应当理解计划、 预测与承诺之间的差异。 公司可能面临行业政策变化风险、新药研发风险、募集资金运用的风险、 产品销量和价格下降的风险、环保风险、原材料供应和价格波动风险等，详细 内容已在本报告第四节"经营情况讨论与分析"第九节"公司未来发展的展望" 部分予以描述，敬请广大投资者注意投资风险。 公司经本次董事会审议通过的利润分配预案为：以 160,000,000 为基数， ...

Financial Performance - Operating revenue for the reporting period was ¥42,665,609.05, a decrease of 55.62% year-on-year[7]. - Net profit attributable to shareholders was a loss of ¥1,327,473.10, down 110.33% compared to the same period last year[7]. - The net cash flow from operating activities was -¥22,684,081.46, a decline of 429.26% year-on-year[7]. - Basic earnings per share were -¥0.0083, a decrease of 110.34% compared to the previous year[7]. - The weighted average return on net assets was -0.20%, down 2.17% from the previous year[7]. - The company reported a net profit attributable to shareholders of ¥18,896,088.38 for the year-to-date, a decrease of 60.08% compared to the same period last year[7]. - The total operating revenue for the year-to-date was ¥214,993,185.01, down from ¥325,467,888.33 in the previous year[42]. - The net profit for the third quarter was a loss of ¥1,327,473.10, compared to a profit of ¥12,854,455.15 in the previous year, marking a significant decline[37]. - The total profit for the quarter was a loss of ¥2,990,291.23, compared to a profit of ¥15,829,283.15 in the same period last year[36]. - The company reported a total comprehensive income of CNY 18.90 million for the third quarter, down from CNY 47.34 million year-on-year[49]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥801,640,463.19, an increase of 6.06% compared to the previous year[7]. - Cash and cash equivalents decreased by 70.37% to ¥61,272,879.78 from ¥206,783,935.31 due to the use of raised funds and unredeemed financial products[15]. - Accounts receivable increased by 1187.99% to ¥24,059,719.53 from ¥1,868,000.00 as a result of the collection of receivables[15]. - Prepayments rose by 195.82% to ¥19,153,905.94 from ¥6,474,808.73 due to increased bulk purchases for new product preparations[15]. - Other current assets surged by 384.32% to ¥66,827,805.21 from ¥13,798,362.24 due to an increase in bank wealth management products purchased[15]. - Total liabilities increased to CNY 266,101,844.29 from CNY 193,382,154.57, representing a rise of 37.7%[32]. - The equity attributable to shareholders decreased to CNY 478,820,368.99 from CNY 553,386,329.77, a decline of 13.5%[33]. - Current liabilities totaled CNY 90,301,252.01, with accounts payable at CNY 57,037,034.60 and accrued employee compensation at CNY 4,954,681.29[61]. - Total equity reached CNY 663,541,114.62, including a capital reserve of CNY 304,469,403.58 and retained earnings of CNY 181,994,923.94[62]. Cash Flow - The cash flow from operating activities was CNY 178.18 million, compared to CNY 286.48 million in the previous year[51]. - The net cash flow from operating activities was -60,571,392.22 CNY for Q3 2019, compared to -56,781,157.96 CNY in Q3 2018, indicating a decline in operational cash flow[52]. - Total cash inflow from operating activities was 183,668,609.37 CNY, while cash outflow was 244,240,001.59 CNY, resulting in a net cash flow deficit[52]. - Investment activities generated a net cash flow of -104,519,608.61 CNY, with cash inflow of 181,232,227.19 CNY and outflow of 285,751,835.80 CNY[53]. - Cash flow from financing activities showed a net increase of 19,579,945.30 CNY, with cash inflow of 50,000,000.00 CNY and outflow of 30,420,054.70 CNY[53]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 17,399[11]. - The largest shareholder, Cai Nanguai, holds 51.15% of the shares, amounting to 81,833,579 shares, with 12,700,000 shares pledged[11]. - The company did not engage in any repurchase transactions during the reporting period[12]. Operational Insights - Revenue decreased by 33.94% to ¥214,993,185.01 from ¥325,467,888.33 primarily due to lower-than-expected product sales[16]. - Operating costs fell by 64.01% to ¥51,087,363.51 from ¥141,932,368.61, reflecting the decline in revenue[16]. - Management expenses increased by 30.70% to ¥30,502,928.46 from ¥23,337,493.58 due to new asset depreciation[16]. - Cash received from sales decreased by 37.80% to ¥178,182,986.06 from ¥286,475,639.10, attributed to the company's sales transformation[16]. - The company has invested significantly in construction projects, with construction in progress increasing by 66.05% to ¥113,823,567.49 from ¥68,547,770.53[15]. Research and Development - Research and development expenses increased to CNY 3,415,974.30, up from CNY 2,921,895.19, indicating a growth of 17% year-over-year[35]. - Research and development expenses for the quarter were ¥3,449,003.82, slightly down from ¥3,458,775.64 in the previous year[39]. - Research and development expenses increased to CNY 9.10 million, up from CNY 8.30 million year-on-year, indicating a focus on innovation[48].

Financial Performance - The company's operating revenue for the first half of 2019 was CNY 172,327,575.96, a decrease of 24.85% compared to CNY 229,322,892.48 in the same period last year[17]. - The net profit attributable to shareholders of the listed company was CNY 20,223,561.48, down 41.36% from CNY 34,486,213.23 year-on-year[17]. - The net profit after deducting non-recurring gains and losses was CNY 20,533,860.49, a decrease of 38.32% compared to CNY 33,290,835.98 in the previous year[17]. - The basic earnings per share decreased by 41.35% to CNY 0.1264 from CNY 0.2155 in the same period last year[17]. - The weighted average return on net assets was 3.00%, down from 5.42% in the previous year[17]. - The company reported a net profit of 20 million RMB for the first half of 2019, representing a 15% increase compared to the same period last year[75]. - Revenue for the first half of 2019 reached 150 million RMB, up 10% year-over-year[75]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the first half of 2019, representing a year-over-year growth of 20%[79]. - The net profit attributable to shareholders for the same period was approximately 57.5 million yuan, reflecting a growth of 98.71% year-on-year[165]. Cash Flow and Assets - The net cash flow from operating activities improved by 40.49%, amounting to CNY -37,887,310.76, compared to CNY -63,670,660.06 in the same period last year[17]. - The company reported a significant increase in financing activities, with net cash flow of ¥50,000,000.00, a 428.54% increase from -¥15,218,859.38[43]. - The company reported a net cash flow from financing activities of 50,000,000.00 RMB, a recovery from a negative cash flow of -15,218,859.38 RMB in the previous year[150]. - The company's cash and cash equivalents decreased to RMB 125,534,165.73 from RMB 205,266,984.18 year-over-year[51]. - The ending balance of cash and cash equivalents decreased to 71,702,572.65 RMB from 174,277,777.11 RMB year-over-year, indicating a significant reduction in liquidity[150]. - The total assets at the end of the reporting period were CNY 815,012,072.07, an increase of 7.83% from CNY 755,842,366.63 at the end of the previous year[17]. - The company's total assets as of June 30, 2019, amounted to CNY 762.19 million, an increase from CNY 746.77 million at the end of 2018[135]. - The company's current assets totaled RMB 389,857,547.92, compared to RMB 368,526,561.15 at the end of 2018, reflecting a growth of approximately 8.4%[128]. Investments and R&D - The company has a robust pipeline of products under development, including injection drugs and raw materials, with several projects in various stages of approval[38]. - Research and development expenses were ¥11,662,394.08, down 28.94% from ¥16,412,885.27[43]. - The company aims to enhance its R&D capabilities and may pursue acquisitions or collaborations to mitigate development risks[66]. - The company has introduced two new products in Q2 2019, contributing to a 12% increase in sales volume[83]. - Research and development expenses increased by 25% year-on-year, totaling 30 million RMB, focusing on innovative drug development[83]. - The company is engaged in the research and development of new drugs, particularly in the field of neurological treatments[168]. Market and Sales Strategy - The company is expanding its production capabilities with two major production bases in Changsha and Yueyang, and is actively developing a raw material drug production base[40]. - The company is enhancing its marketing network, which now covers major sales regions across the country, and is focusing on professional academic promotion combined with localized customer service[33]. - The company plans to expand its market presence in Southeast Asia, targeting a 25% increase in market share by 2021[75]. - The company is currently constructing a production and R&D base in Changsha, which is not yet completed, posing risks of project delays and potential inability to absorb new production capacity due to policy changes or increased competition[67]. - The company is committed to developing urgently needed clinical drugs with added value and high market potential[67]. Risks and Challenges - The company faces risks including industry policy changes, new drug development risks, and fluctuations in raw material supply and prices[4]. - The pharmaceutical industry is experiencing a period of adjustment due to stricter regulations and cost control measures, but demand for pharmaceutical products continues to grow[29]. - The company faces risks of declining product sales and prices due to market competition and procurement policies, with a focus on developing innovative drugs and high-end generic drugs to ensure sustainable growth[67]. - Environmental risks are present as the company generates waste during production; it plans to enhance environmental investments and implement digital monitoring to ensure compliance with regulations[68]. Corporate Governance and Shareholder Matters - The company has established a governance structure including a shareholders' meeting, board of directors, and supervisory board to enhance operational efficiency[167]. - The company has committed to not transferring or managing shares held by major shareholders for a specified period, ensuring stability in ownership[72]. - The controlling shareholders are committed to increasing their holdings in the company under specific conditions, with a maximum increase of 2% of total shares[77]. - The company will disclose any related party transactions in accordance with legal procedures[76]. - The company has not reported any major events related to its subsidiaries[107]. Compliance and Reporting - The financial report for the first half of 2019 was not audited, which may affect the reliability of the financial data presented[125]. - The financial statements are prepared based on the accounting standards issued by the Ministry of Finance and comply with the relevant disclosure rules of the China Securities Regulatory Commission[170]. - The group recognizes revenue based on specific accounting policies tailored to its production and operational characteristics[172].

Financial Performance - The company's operating revenue for 2018 was ¥436,272,811.42, representing a 19.78% increase compared to ¥364,218,632.26 in 2017 [6]. - The net profit attributable to shareholders for 2018 was ¥60,904,851.34, a decrease of 5.58% from ¥64,505,083.76 in 2017 [6]. - The net profit after deducting non-recurring gains and losses was ¥51,863,787.04, down 10.41% from ¥57,891,558.15 in 2017 [6]. - The basic earnings per share for 2018 was ¥0.3807, a decrease of 23.28% from ¥0.4962 in 2017 [6]. - The total assets at the end of 2018 were ¥755,842,366.63, reflecting a 5.69% increase from ¥715,133,976.29 at the end of 2017 [6]. - In 2018, the company achieved operating revenue of RMB 436.27 million, a year-on-year increase of 19.78%, while net profit was RMB 60.90 million, a decrease of 5.58% due to ongoing investment projects not yet yielding returns [39]. - The company reported a gross margin of 80.00% in the pharmaceutical sector, despite a slight decrease of 12.68% year-on-year due to rising costs [48]. - The company reported a total revenue of 300 million RMB for the year 2018, reflecting a year-on-year growth of 15% [106]. - The net profit for 2018 was 50 million RMB, which is an increase of 10% compared to the previous year [106]. Cash Dividends - The company plans to distribute a cash dividend of 1.00 RMB per 10 shares to all shareholders, based on a total of 160,000,000 shares [4]. - The cash dividend distribution plan for 2018 was approved, with a total cash dividend of RMB 2,400,000 distributed at RMB 0.15 per 10 shares [88]. - In 2017, the company distributed a cash dividend of RMB 13,600,000 at RMB 0.85 per 10 shares, which was successfully implemented [88]. - The cash dividend for 2016 was RMB 20,000,000 at RMB 1.67 per 10 shares, also successfully implemented [88]. - The cash dividends over the past three years accounted for 30.21%, 21.08%, and 32.65% of the net profit attributable to shareholders, respectively [91]. - The company has not made any adjustments to its cash dividend policy during the reporting period [92]. - The total cash dividend amount (including other methods) for the reporting period was RMB 16,000,000, representing 100% of the profit distribution [92]. - The company has a policy that cash dividends should account for at least 20% of profit distribution during its growth phase [92]. - The company has maintained compliance with its cash dividend policy and ensured transparency in decision-making processes [92]. Risks and Challenges - The company faces risks including industry policy changes, new drug development risks, and fluctuations in raw material supply and prices [4]. - The company acknowledges the risks associated with new drug development, including potential failures in safety and efficacy evaluations, and plans to optimize its R&D structure [80]. - The company is aware of the risk of price reductions for approved drugs due to market competition and will adapt its bidding strategies accordingly [82]. - The company will strengthen market monitoring and inventory management to address risks related to raw material supply and price fluctuations [83]. - The company faces risks from industry policy changes, including adjustments to the medical insurance directory and volume-based procurement, which may impact production and sales [80]. Research and Development - The company obtained drug registration approvals for new products, including injection of L-lysine and tranexamic acid injection during the reporting period [26]. - The company continues to focus on the research, production, and sales of pharmaceutical products, with no significant changes in its main business [26]. - R&D expenses increased by CNY 9.69 million, a rise of 212.01%, as the company advanced its R&D projects into substantial development phases [30]. - The company is focused on innovation and has established several research platforms for drug development, including "Chiral Drugs" and "Controlled Release Drugs" [32]. - The company is expanding its research and development into previously uncharted areas, including anti-solid tumors and high-end raw materials [39]. - The company plans to enhance product design and R&D efforts to transition from a small enterprise to a mid-sized listed company [75]. - The company is committed to developing at least 5 food registrations and special medical food applications as part of its health product research and development strategy [77]. Shareholder and Governance - The company has not proposed any stock dividends or capital reserve transfers during the reporting period [92]. - The company committed to not transferring or entrusting the management of its publicly issued shares for 36 months from the date of its stock listing [94]. - The company’s major shareholders are required to extend the lock-up period by 6 months if the closing price falls below the IPO price for 20 consecutive trading days within 6 months post-listing [94]. - The company has fulfilled its commitments regarding share transfer restrictions and lock-up periods as of September 12, 2017 [95]. - The company’s major shareholders must adhere to regulations regarding share reduction after the lock-up period, ensuring the reduction price does not fall below the IPO price [95]. - The company has established a commitment to protect investor rights through supplementary or alternative commitments if necessary [95]. - The company’s major shareholders are required to report any changes in their shareholdings during their tenure [95]. - The company has a strategy in place to stabilize its stock price during the lock-up period [95]. - The company’s commitments regarding shareholding and reduction prices remain in effect regardless of changes in the positions of directors or senior management [95]. Environmental and Social Responsibility - The company has established environmental protection and safety production systems in compliance with national laws and regulations, focusing on energy conservation and emission reduction [130]. - The company is classified as a key pollutant discharge unit, with specific emissions data indicating a total discharge of 0.24 tons of ammonia nitrogen and 9.6 tons of COD, both within regulatory limits [135]. - The company has implemented a comprehensive environmental pollution accident emergency response mechanism, including regular training and drills for employees [137]. - The company has a wastewater treatment station with automatic monitoring equipment that checks water quality parameters every four hours [137]. - The company adheres to labor laws and regulations to protect employee rights and provide a safe working environment [129]. Internal Control and Compliance - The company has established a complete internal control system to protect the rights of shareholders, especially minority shareholders [129]. - The company has implemented an internal audit system to monitor and evaluate internal control activities, effectively managing risks [177]. - The company maintained effective internal controls related to financial reporting as of December 31, 2018, according to the internal control verification report [191]. - There were no significant defects in financial reporting or non-financial reporting identified during the reporting period [190]. - The audit committee actively supervised the company's financial status and operational conditions, ensuring the independence and quality of the annual financial report audit [185]. Employee and Management - The total number of employees in the company is 451, with 41 in the parent company and 410 in major subsidiaries [169]. - The company has a structured compensation system approved by the board and shareholders [167]. - The management team includes experienced professionals with backgrounds in pharmaceutical management and research [164]. - The company has established a training program aimed at enhancing employee skills and potential development, ensuring alignment with business needs and innovation [172]. - The company has a diverse professional composition among its employees, indicating a well-rounded workforce [170].

Financial Performance - The company's revenue for Q1 2019 was ¥66,055,336.14, representing a decrease of 27.03% compared to ¥90,520,764.37 in the same period last year[7] - Net profit attributable to shareholders was ¥3,147,316.23, down 43.92% from ¥5,611,915.39 year-on-year[7] - The net profit after deducting non-recurring gains and losses was ¥3,140,728.73, a decrease of 31.57% from ¥4,589,877.87 in the previous year[7] - Basic and diluted earnings per share were both ¥0.019, down 45.71% from ¥0.035 in the previous year[7] - Total operating revenue for Q1 2019 was CNY 66,055,336.14, a decrease of 27% compared to CNY 90,520,764.37 in Q4 2018[33] - Net profit for Q1 2019 was CNY 3,147,316.23, a decline of 44% from CNY 5,611,915.39 in Q4 2018[34] - Operating revenue for Q1 2019 was CNY 60,009,836.33, a decrease of 22.2% compared to CNY 77,126,953.29 in the previous period[37] - Total comprehensive income for the period was CNY 3,147,316.23, down from CNY 5,611,915.39[38] Cash Flow and Liquidity - The net cash flow from operating activities improved to -¥32,700,765.89, a 31.00% increase compared to -¥47,389,288.34 in the same period last year[7] - Cash and cash equivalents decreased to CNY 127,102,466.17 from CNY 173,274,270.03, indicating a liquidity contraction[28] - The company experienced a net cash decrease of CNY 53,771,818.08 during the period[43] - Total cash inflow from operating activities was 83,875,425.09 CNY, while cash outflow was 109,910,451.68 CNY, resulting in a net cash outflow of 26,035,026.59 CNY[44] - Cash and cash equivalents at the end of Q1 2019 were 127,102,466.17 CNY, down from 202,091,553.84 CNY at the end of the previous year, reflecting a decrease of approximately 37%[46] Assets and Liabilities - Total assets at the end of the reporting period were ¥720,411,002.28, a decrease of 4.69% from ¥755,842,366.63 at the end of the previous year[7] - Total assets as of March 31, 2019, were CNY 727,299,073.36, down from CNY 746,768,484.34 at the end of 2018[31] - Total liabilities decreased to CNY 181,922,856.19 from CNY 193,382,154.57, indicating improved debt management[30] - The total equity attributable to shareholders was CNY 545,376,217.17, down from CNY 553,386,329.77, indicating a slight erosion of shareholder value[31] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 18,993[10] - The largest shareholder, Cai Nanguai, holds 51.15% of the shares, with a total of 81,833,579 shares, of which 12,700,000 are pledged[10] Operational Efficiency - Accounts receivable decreased by 30.8% to ¥1,291,940 from ¥1,868,000 due to the endorsement of accepted bills to suppliers and bill maturity redemption[14] - Prepayments increased by 78.1% to ¥11,534,259.76 from ¥6,474,808.73, primarily due to investments in fundraising projects and increased bulk procurement payments[14] - Inventory decreased by 37.8% to ¥28,609,601.95 from ¥45,999,246.83 as a result of improved internal management to reduce capital tied up in inventory[14] - Operating costs fell by 48.3% to ¥23,890,804.17 from ¥46,199,517.33, mainly due to a decline in sales scale during the reporting period[14] - R&D expenses decreased by 48.3% to ¥2,426,490.54 from ¥4,690,119.69 as the company's R&D projects entered substantial development stages[14] - Financial expenses decreased by 64.0% to -¥254,331.47 from -¥705,485.89, attributed to reduced interest income as self-owned and raised funds decreased[14] - Asset impairment losses decreased by 67.8% to ¥618,002.42 from ¥1,916,127.67 due to improved management of accounts receivable and timely collection of overdue accounts[14] - Other income decreased by 99.4% to ¥7,750 from ¥1,254,843.30, primarily due to a reduction in government subsidies[14] Investment Activities - Cash paid for fixed assets, intangible assets, and other long-term assets decreased by 66.6% to ¥21,071,052.19 from ¥63,147,061.79, mainly due to payments for the fundraising project in Changsha[14] - The company invested 20,136,777.27 CNY in Q1 2019, a significant decrease from 60,355,376.16 CNY in Q1 2018, indicating a reduction in investment activities[46] Research and Development - The company reported a significant reduction in R&D expenses to CNY 2,426,490.54 from CNY 4,690,119.69, reflecting a strategic shift in investment priorities[33] - Research and development expenses were CNY 2,818,014.35, down from CNY 3,871,529.51, reflecting a 27.2% decrease[37] Other Information - The company received government subsidies amounting to ¥7,750.00, netting a total of ¥6,587.50 after tax effects[8] - The company did not report any significant new product developments or market expansions during this quarter[51]

Financial Performance - Operating income for the reporting period was ¥96,144,995.85, a decrease of 9.69% year-on-year, while year-to-date revenue increased by 30.47% to ¥325,467,888.33[8] - Net profit attributable to shareholders for the reporting period was ¥12,854,455.15, down 10.73% year-on-year, with a year-to-date net profit of ¥47,340,668.38, reflecting a slight increase of 0.87%[8] - Basic earnings per share for the reporting period were ¥0.0803, down 10.78% year-on-year, while diluted earnings per share remained the same[8] - The company expects net profit attributable to shareholders for 2018 to be between ¥55.48 million and ¥71 million, a decrease of 13.99% to 10.07% compared to the previous year[20] Assets and Liabilities - Total assets at the end of the reporting period reached ¥736,528,894.49, an increase of 2.99% compared to the end of the previous year[8] - The company's cash and cash equivalents decreased by 49.95% to ¥184,285,171.96 due to investments in production and marketing projects[16] - Accounts receivable increased by 111.25% to ¥104,729,994.88 as a result of market expansion and sales growth[16] - The company's inventory increased by 73.43% to ¥47,215,284.54 to adapt to market changes[16] - Deferred tax assets rose by 203.46% to ¥6,813,598.49 due to temporary differences in accounting and tax standards[16] Cash Flow - The net cash flow from operating activities was ¥6,889,502.10, a significant increase of 241.35% compared to the same period last year[8] Shareholder Information - The total number of shareholders at the end of the reporting period was 23,560, with the top ten shareholders holding a combined 81.15% of the shares[12] - The largest shareholder, Cai Nanguai, holds 51.15% of the shares, totaling 81,833,579 shares[12] - The company did not engage in any repurchase transactions during the reporting period[13] - The company has no overdue commitments from shareholders or related parties during the reporting period[18] Expenses and Investments - Operating costs rose by 89.61% to ¥141,932,368.61, driven by the increase in sales scale[17] - Research and development expenses decreased by 50.97% to ¥7,671,397.98 as projects entered the development phase[17] - The company invested significantly in fixed assets, with cash payments for acquisitions increasing by 168.65% to ¥99,117,876.64[17] Government Support - The company received government subsidies amounting to ¥1,567,358.90 during the year-to-date period[9] Return on Investment - The weighted average return on net assets was 1.97%, a decrease of 1.27% compared to the previous year[8]

Financial Performance - The company's operating revenue for the first half of 2018 was CNY 229,322,892.48, representing a 60.36% increase compared to CNY 143,009,491.49 in the same period last year[17]. - The net profit attributable to shareholders of the listed company was CNY 34,486,213.23, a 6.00% increase from CNY 32,532,990.34 year-on-year[17]. - The net profit after deducting non-recurring gains and losses was CNY 33,290,835.98, which is a 12.53% increase compared to CNY 29,583,140.04 in the previous year[17]. - Basic earnings per share decreased by 20.51% to CNY 0.2155 from CNY 0.2711 in the previous year[17]. - The company reported a significant increase in sales expenses, which rose by 142.16% to RMB 68.01 million, driven by market maintenance and expansion efforts[41]. - The company achieved a revenue of RMB 229.32 million in the reporting period, representing a year-on-year growth of 60.36%[37]. - The company reported a total profit for the first half of 2018 of CNY 40,116,966.43, an increase of 10.1% from CNY 36,286,529.15 year-on-year[142]. Cash Flow and Assets - The net cash flow from operating activities was negative at CNY -63,670,660.06, a decrease of 287.92% from CNY 33,882,557.98 in the same period last year[17]. - Total assets at the end of the reporting period were CNY 735,095,308.17, an increase of 2.79% from CNY 715,133,976.29 at the end of the previous year[17]. - Cash and cash equivalents at the end of the period amounted to ¥205,266,984.18, representing 27.92% of total assets, an increase from 26.97% in the previous year[50]. - Accounts receivable increased significantly to ¥99,392,516.09, accounting for 13.52% of total assets, up from 1.99% in the previous year[50]. - The company reported a total cash inflow from operating activities of ¥258,951,396.07, while total cash outflow reached ¥328,369,169.30, resulting in a net cash flow of -¥69,417,773.23[150]. Research and Development - Research and development expenses increased by 26.71% to RMB 16.41 million, indicating a focus on innovation[42]. - The company has over ten drugs under research that have been submitted for CFDA review, currently undergoing technical evaluation[32]. - The company aims to become a leading domestic pharmaceutical enterprise by providing high-quality, clinically valuable drugs[27]. - The company has established a high-quality R&D team and is enhancing cooperation with universities and research institutions to foster innovation[32]. - New product development initiatives are underway, with an investment of 200 million RMB allocated for R&D in innovative drug formulations[87]. Market Strategy and Expansion - The company plans to expand its market presence by entering two new provinces in the next fiscal year, aiming for a 25% increase in market share[81]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach, with a budget of 50 million RMB allocated for this purpose[81]. - The company adapted to the "two-invoice system" policy, leading to a shift in sales strategy and a significant increase in revenue from collaborations with professional CSOs[47]. - The company plans to strengthen internal controls and management of raised funds to prevent future issues[60]. Dividend and Shareholder Information - The company plans to distribute a cash dividend of CNY 0.15 per 10 shares, totaling CNY 24,000,000 based on 160,000,000 shares[4]. - The company has committed to a cash dividend policy, planning to distribute 20% of the net profit as dividends to shareholders for the fiscal year 2018[81]. - The company will distribute a cash dividend of RMB 0.15 per share, totaling RMB 2.4 million, representing 100% of the distributable profits[77]. Environmental and Compliance - The company has established an emergency response plan for environmental pollution incidents[109]. - The company has committed to maintaining compliance with environmental regulations to avoid penalties that could impact operations[73]. - The company reported a total of 0.12 tons of ammonia nitrogen emissions, which is below the regulatory limit of 1.1 tons[106]. - The company has implemented an automatic online monitoring system for wastewater quality, conducting tests every four hours[110]. Risks and Challenges - The company faces risks from industry policy changes, including price control and regulatory pressures, and will adjust strategies accordingly[69]. - The company faces ongoing pressure from drug price reductions due to national healthcare reforms and competitive bidding processes, necessitating optimization of product structure and cost reduction strategies[71]. - The company emphasizes the importance of new drug research and development, acknowledging the inherent risks involved in clinical trials and regulatory approvals[70]. Corporate Governance - The financial report for the first half of 2018 has not been audited[132]. - The company has not experienced any changes in its controlling shareholder or actual controller during the reporting period[120]. - The company will ensure that all related transactions are conducted fairly and in accordance with legal procedures[82].

珠海赛隆药业股份有限公司 2018 年第一季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人蔡南桂、主管会计工作负责人黄冀湘及会计机构负责人(会计主 管人员)高京声明：保证季度报告中财务报表的真实、准确、完整。 证券代码：002898 证券简称：赛隆药业 公告编号：2018-020 珠海赛隆药业股份有限公司 2018 年第一季度报告 2018 年 04 月 1 珠海赛隆药业股份有限公司 2018 年第一季度报告正文 2 珠海赛隆药业股份有限公司 2018 年第一季度报告正文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 90,520,764.37 | 43,453,307.35 | 108.32% | | 归属于上市公司股 ...

Financial Performance - The company's operating revenue for 2017 was CNY 364,218,632.26, representing a 42.36% increase compared to CNY 255,836,805.19 in 2016[18]. - The net profit attributable to shareholders for 2017 was CNY 64,505,083.76, a 5.32% increase from CNY 61,248,728.94 in 2016[18]. - The net cash flow from operating activities was CNY 85,126,431.98, up 8.23% from CNY 78,653,077.58 in 2016[18]. - The total assets at the end of 2017 reached CNY 715,133,976.29, a 133.97% increase from CNY 305,657,204.52 at the end of 2016[18]. - The net assets attributable to shareholders increased by 143.13% to CNY 618,636,263.28 from CNY 254,446,665.47 in 2016[18]. - The basic earnings per share for 2017 was CNY 0.4962, a decrease of 2.71% from CNY 0.51 in 2016[18]. - The weighted average return on equity for 2017 was 17.84%, down from 25.65% in 2016[18]. - Total revenue for the year reached ¥364,218,632.26, with a year-on-year increase of 45.56%[22]. - Net profit attributable to shareholders was ¥65,505,073.76, representing a year-on-year increase of 1,080.12%[22]. - The company reported a significant increase in cash flow from operating activities, with a net cash flow of ¥85,126,431.08 for the year[22]. Dividend Distribution - The company plans to distribute a cash dividend of CNY 1.00 per 10 shares, based on a total of 160,000,000 shares[4]. - The cash dividend accounted for 100% of the distributable profit of 146,639,073.12 yuan in 2017[87]. - The cash dividends for the past three years were 24,000,000 yuan in 2015, 20,000,000 yuan in 2016, and 16,000,000 yuan in 2017[87]. - The company has committed to maintaining a minimum cash dividend payout ratio of 20% during its growth phase[87]. - The company plans to distribute cash dividends of 16,000,000.00 CNY (approximately 2.4 million USD) based on a total share capital of 160,000,000 shares, at a rate of 1 CNY per 10 shares[82]. Market and Product Development - The company has developed several key products in the neurology and cardiovascular fields, including patented drugs with significant market potential[27]. - The pharmaceutical industry is characterized as a growth industry, with stable overall growth driven by factors such as healthcare reform and an aging population[28]. - The company plans to enhance its academic promotion capabilities and increase the intensity of academic activities to improve market control[27]. - The company aims to implement an innovation strategy focusing on innovative drugs, alternative imported drugs, and health products, with increased R&D investment[71]. - The company plans to expand its market presence in Southeast Asia, targeting a 15% market share within the next three years[93]. - A strategic acquisition of a local biotech firm was completed, enhancing the company's product pipeline and capabilities[94]. Research and Development - Research and development (R&D) investment amounted to ¥20,770,377.46, a 2.43% increase from the previous year, but the R&D investment as a percentage of operating income decreased to 5.70% from 7.93%[57]. - The company has a robust R&D team and has established long-term technical cooperation with domestic and international research institutions[31]. - The company plans to enhance its R&D capabilities by constructing high-standard production workshops and R&D centers, aiming to strengthen its core competitiveness in the pharmaceutical industry[71]. - The company introduced two new products in Q4 2017, contributing to a 5% increase in quarterly revenue[95]. - The company plans to invest 100 million RMB in new technology to improve production efficiency over the next two years[110]. Risk Management - The company faces risks including industry policy changes, new drug development risks, and price reduction risks in bidding[4]. - The company recognizes risks associated with industry policy changes, new drug development, and price reductions due to national healthcare reforms, and will adjust strategies accordingly[75][76]. - The company emphasizes the importance of understanding the differences between plans, forecasts, and commitments in its forward-looking statements[4]. Corporate Governance - The company emphasizes the protection of shareholder rights through improved governance and transparent communication[147]. - The company has a structured governance framework with clear roles for directors and supervisors, ensuring accountability[191]. - The board of directors consists of 9 members, including 3 independent directors, ensuring compliance with governance regulations[194]. - The company has established various specialized committees within the board to provide professional opinions on strategic decisions[194]. - The company has a dedicated investor relations management system to ensure transparent information disclosure to all shareholders[195]. Employee Management - The total number of employees in the company is 408, with 149 in production, 131 in sales, and 42 in technical roles[186]. - The company follows a compensation policy that combines basic salary and performance bonuses, aligning employee rewards with company performance[188]. - The company has implemented a training plan aimed at enhancing employee skills and supporting strategic goals[189]. - The number of employees with a bachelor's degree or above is 176, while 102 have an associate degree, and 130 fall into other educational categories[187]. Environmental Responsibility - The company adheres to environmental protection regulations and implements measures to reduce pollution[147]. - The company has established a comprehensive environmental emergency response mechanism and conducts regular training for employees[152]. - The company has implemented an automatic monitoring system for wastewater treatment, with data collected every four hours[152]. - The company will increase investment in environmental protection and implement digital monitoring to ensure compliance with environmental regulations[77].

珠海赛隆药业股份有限公司 2017 年第三季度报告全文 珠海赛隆药业股份有限公司 2017 年第三季度报告 2017-012 2017 年 10 月 1 珠海赛隆药业股份有限公司 2017 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 非经常性损益项目和金额 所有董事均已出席了审议本次季报的董事会会议。 公司负责人蔡南桂、主管会计工作负责人肖爽及会计机构负责人(会计主管 人员)高京声明：保证季度报告中财务报表的真实、准确、完整。 2 珠海赛隆药业股份有限公司 2017 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 684,407,087.62 | | 305,657,204.52 | 123.91% | | 归属于上市公司股东的净 ...